A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Keyphrases

• Major Depressive Disorder 100%
• Treatment-resistant Depression 100%
• Randomized Trial 100%
• N-methyl-D-aspartate Receptor Antagonist 100%
• Confidence Interval 66%
• Placebo 66%
• Ketamine 66%
• Mood Disorders 66%
• Rapid-acting Antidepressant 66%
• Randomized Placebo-controlled Trial 33%
• Pathophysiology 33%
• Antidepressants 33%
• DSM-IV 33%
• Depression Treatment 33%
• After Injection 33%
• Remission Criteria 33%
• National Institute of Mental Health 33%
• N-methyl-D-aspartate Receptor (NMDAR) 33%
• Ketamine Hydrochloride 33%
• Drug-free 33%
• Change of Measure 33%
• Efficacy Index 33%
• Hamilton Depression Rating Scale (HAM-D) 33%
• Glutamatergic System 33%
• Intravenous Infusion 33%
• Treatment-resistant 33%
• Intravenous Dose 33%
• Onset of Action 33%
• Rapid Onset 33%
• Lines of Evidence 33%
• Impact on Care 33%
• Pharmacological Strategies 33%
• Ketamine Infusion 33%
• Free-running Period 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Treatment Resistant Depression 100%
• Ketamine 100%
• Aspartic Acid 100%
• Placebo 75%
• Antidepressant 75%
• Mood Disorder 50%
• Major Depression 50%
• Pathophysiology 25%
• Remission 25%
• Receptor 25%
• DSM-IV 25%

Neuroscience

• Aspartic Acid 100%
• Treatment-Resistant Depression 100%
• Ketamine 100%
• Antidepressant 75%
• Placebo 75%
• Major Depressive Disorder 50%
• Mood Disorder 50%
• Chloride 25%
• Crossover Study 25%
• Hamilton Rating Scale for Depression 25%
• Receptor 25%